The Siemens sector Healthcare has developed the new consulting model “Act on Stroke”, tailored specifically to clinical workflows in the treatment of stroke.
Following models for industry processes, an expert team from Siemens evaluates the maturity level of clinical processes in a hospital. Based on a data pool that integrates the knowledge of leading hospitals worldwide, Siemens consultants support the optimization of clinical workflows, aiming at measurably higher quality of care for stroke patients.
At Medica 2010, Siemens presents the new approach and first consultation projects with “Act on Stroke”.
“Time is Brain” is a key principle in neurology and expresses the importance of time with respect to stroke care: the quicker a patient is diagnosed and treated appropriately, the greater the probability that he may recover from possible brain damage. However, the processes and guidelines for optimal stroke care are not maintained consistently. In Europe, less than 40 percent of the hospitals meet the minimum standards for stroke care.1
In Germany, only approximately half of the stroke patients are treated in a stroke unit, that is, a specialized stroke ward.2 And in the USA, only 4.3 percent of patients with a cerebral infarct receive timely thrombolytic treatment3 – the current stroke therapy that dissolves the blood clot (thrombus) causing reduced blood supply to the brain. With "Act on Stroke“, Siemens has developed a new consulting concept for improved stroke care management. The model integrates the analyses of processes from hospitals leading the field of stroke care worldwide and combines them with medical guidelines and current scientific results. “Act on Stroke” is backed by an interdisciplinary expert team from Siemens: physicians, strategy and workflow consultants, as well as economists, IT experts, engineers, and medical technicians.
In only five days, two of the Siemens consultants analyze the stroke processes in a hospital. Based on more than 450 individual criteria, they determine the maturity level of complex clinical processes on a scale from 1 to 5. After having evaluated the status quo and provided a detailed report, the consultants develop actions for the customer that enable workflows to be both measured and sustainably optimized with respect to time and adherence to guidelines. For example, thrombolytic therapy should be started no later than four and a half hours after onset of the first symptoms.
Siemens has yet successfully applied “Act on Stroke” to several customer sites, among them the University Clinic of Muenster, Germany, where Professor Bernd Ringelstein, MD, heads the Clinic and Polyclinic for Neurology. “Siemens analyzed the stroke processes at our hospital in a very impressive and convincing way. The recommended actions will help us to overcome residual obstacles within our processes efficiently,” says Ringelstein. Siemens aims to complete the “Act on Outcomes” program by adding other relevant areas of care, for example, the treatment of cardiac insufficiency. So far, the model has been developed for stroke and for acute coronary syndrome.
The Siemens Healthcare Sector is one of the world’s largest healthcare solution providers and a leading manufacturer and service provider in the fields of medical imaging, laboratory diagnostics, hospital information technology and hearing instruments. Siemens offers its customers products and solutions for all aspects of patient care under one roof - from prevention and early detection and diagnosis to therapy and aftercare. By optimizing the clinical workflows designed to deal with the major disease patterns, Siemens also ensures that healthcare becomes faster, better and at the same time more cost-effective.1 Leys, D., et al: „Facilities Available in European Hospitals Treating Stroke Patients“, Stroke 2007 38; p.2985-2991
High Resolution Laser Structuring of Thin Films at LOPEC 2017
21.03.2017 | Fraunhofer-Institut für Lasertechnik ILT
Open ecosystem for smart assistance systems
20.03.2017 | Fraunhofer-Institut für Arbeitswirtschaft und Organisation IAO
Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.
The results will be published on March 22 in the journal „Astronomy & Astrophysics“.
Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...
Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.
Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...
In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...
Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.
Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...
20.03.2017 | Event News
14.03.2017 | Event News
07.03.2017 | Event News
23.03.2017 | Life Sciences
23.03.2017 | Power and Electrical Engineering
23.03.2017 | Earth Sciences